N-acetyl cysteine + alpha lipoic acid + liposomal glutathione + Novartis influenza vaccine

This combination therapy consists of three antioxidant compounds—**N-acetyl cysteine (NAC)**, **alpha lipoic acid (ALA)**, and **liposomal glutathione**—administered in conjunction with a seasonal influenza vaccine developed by **Novartis Vaccines** (such as the MF59-adjuvanted **Fluad** or the unadjuvanted **Agrippal**). NAC is a thiol-containing derivative of the amino acid L-cysteine that serves as a rate-limiting precursor for the synthesis of glutathione, the body's primary endogenous antioxidant. Alpha lipoic acid is a potent metabolic antioxidant and enzymatic cofactor that helps regenerate other antioxidants like Vitamin C and E. Liposomal glutathione is a specialized formulation designed to improve the oral bioavailability of the tripeptide glutathione. The Novartis influenza vaccine component refers to the subunit vaccines evaluated in clinical trials like the **V70P5** extension study, which assessed the immunogenicity and safety of adjuvanted versus non-adjuvanted formulations in pediatric populations. This combination is typically investigated for its potential to modulate the immune response, reduce oxidative stress associated with viral infection, or enhance the safety profile of the immunization.

Brand names

FluadAgrippal

Other names

N-acetyl cysteine + alpha lipoic acid + liposomal glutathione-Novartis Vaccines-influenzaAntioxidant Stack + Novartis Influenza Vaccine